scholarly journals Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism

2011 ◽  
Vol 79 (1) ◽  
pp. 112-119 ◽  
Author(s):  
Katherine Wesseling-Perry ◽  
Renata C. Pereira ◽  
Shobha Sahney ◽  
Barbara Gales ◽  
He-Jing Wang ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Growth Factor ◽  
Bone Turnover ◽  
Secondary Hyperparathyroidism ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Fibroblast Growth

scholarly journals Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

2019 ◽  
Vol 13 (1) ◽  
pp. 75-84 ◽  
Author(s):  
Myles Wolf ◽  
Geoffrey A Block ◽  
Glenn M Chertow ◽  
Kerry Cooper ◽  
Bruno Fouqueray ◽  
...  
Keyword(s):  
Growth Factor ◽  
Bone Turnover ◽  
Secondary Hyperparathyroidism ◽  
Fibroblast Growth Factor ◽  
Bone Turnover Markers ◽  
Calcium Supplementation ◽  
Fibroblast Growth Factor 23 ◽  
Fibroblast Growth ◽  
Secondary Analyses ◽  
Turnover Markers

Abstract Background Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are unknown. Methods To investigate potential mediators of etelcalcetide-induced FGF23 reduction, we performed secondary analyses of the 26-week randomized trials that compared the effects on PTH of etelcalcetide (n = 509) versus placebo (n = 514) and etelcalcetide (n = 340) versus cinacalcet (n = 343) in adults with sHPT receiving hemodialysis. We analyzed changes in FGF23 in relation to changes in PTH, calcium, phosphate and bone turnover markers. We also investigated how concomitant treatments aimed at mitigating hypocalcemia altered the FGF23-lowering effects of etelcalcetide. Results Etelcalcetide reduced FGF23 [median % change (quartile 1–quartile 3)] from baseline to the end of the trial significantly more than placebo [–56% (–85 to –7) versus +2% (–40 to +65); P < 0.001] and cinacalcet [–68% (–87 to –26) versus –41% (–76 to +25); P < 0.001]. Reductions in FGF23 correlated strongly with reductions in calcium and phosphate, but not with PTH; correlations with bone turnover markers were inconsistent and of borderline significance. Increases in concomitant vitamin D administration partially attenuated the FGF23-lowering effect of etelcalcetide, but increased dialysate calcium concentration versus no increase and increased dose of calcium supplementation versus no increase did not attenuate the FGF23-lowering effects of etelcalcetide. Conclusion These data suggest that etelcalcetide potently lowers FGF23 in patients with sHPT receiving hemodialysis and that the effect remains detectable among patients who receive concomitant treatments aimed at mitigating treatment-associated decreases in serum calcium.

scholarly journals Convergent Signaling Pathways Regulate Parathyroid Hormone and Fibroblast Growth Factor-23 Action on NPT2A-mediated Phosphate Transport

2016 ◽  
Vol 291 (36) ◽  
pp. 18632-18642 ◽  
Author(s):  
W. Bruce Sneddon ◽  
Giovanni W. Ruiz ◽  
Luciana I. Gallo ◽  
Kunhong Xiao ◽  
Qiangmin Zhang ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Growth Factor ◽  
Signaling Pathways ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Phosphate Transport ◽  
Fibroblast Growth

The role of fibroblast growth factor 23 vs. parathyroid hormone in hypophosphatemia in long-term kidney transplantation

Bone ◽  
2011 ◽  
Vol 48 ◽  
pp. S148-S149
Author(s):  
S. Disthabanchong⁎ ◽  
S. Sirilak ◽  
V. Sumethkul ◽  
A. Ingsathit ◽  
S. Kantachuvesiri ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Parathyroid Hormone ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Fibroblast Growth

Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion

2008 ◽  
Vol 17 (4) ◽  
pp. 363-367 ◽  
Author(s):  
Hillel Galitzer ◽  
Iddo Ben-Dov ◽  
Vardit Lavi-Moshayoff ◽  
Tally Naveh-Many ◽  
Justin Silver
Keyword(s):  
Parathyroid Hormone ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Hormone Secretion ◽  
Fibroblast Growth
Sign in / Sign up

Export Citation Format

Share Document